Ac-SDKP FAQ: common questions answered
An experimental repair peptide with old human studies, but no proven healing dose.
Also called: AcSDKP, Goralatide, Seraspenide, N-acetyl-seryl-aspartyl-lysyl-proline, Thymosin beta-4 fragment 1–4, TB4-Frag.
Healing and repair peptides · Endogenous tetrapeptide; thymosin beta-4 N-terminal fragment.
- Is Ac-SDKP FDA-approved? No approved product or label located under Ac-SDKP, goralatide or seraspenide. A substance identifier is not approval.
- How do people take it? Under the skin, once daily in the morning. Reports one week off every 2 months; exact on-period in weeks was not stated.. Source: reported by users, not an established dose.
- What's the difference between Ac-SDKP and BPC-157? Ac-SDKP: an experimental repair peptide with old human studies, but no proven healing dose. BPC-157: an experimental repair peptide with mostly animal evidence and a few small human reports. Why people pair them: one repeat poster combines it with Ac-SDKP for recovery. No controlled human trial tested this stack.
- Can I take it with BPC-157? One repeat poster combines it with Ac-SDKP for recovery. No controlled human trial tested this stack. Identity, dosing and combined blood-cell or vessel effects are unresolved. Source: reported by users. Ask a doctor before combining anything.
- Is it banned in sport? It is unclear (WADA 2026). No compound-specific 2026 ruling was verified. Any S0 assessment is conditional on worldwide human therapeutic approvals and applicability of other sections. Ac-SDKP is a different molecule from the LKKTETQ TB-500 fragment.
- How long does a mixed vial last? No validated home-use storage period after mixing was found.
Related to Ac-SDKP
- BPC-157: An experimental repair peptide with mostly animal evidence and a few small human reports.
- TB-500: A short piece of thymosin beta-4 with no proven repair benefit in humans.
- GHK-Cu: A copper-binding skin peptide with small topical studies and untested systemic injections.
- AHK-Cu: A copper peptide used in scalp serums, with laboratory findings and weak patent-only human data.
- Thymosin beta-4: A peptide studied for eye conditions and skin wounds; tendon-repair injections lack controlled human evidence.
- ARA-290: Experimental peptide studied for small-fiber nerve damage, with uncertain pain relief and safety.
Sources
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Concerns regarding the public health risks associated with unapproved peptide products, Therapeutic Goods Administration and Chief Medical Officer · Therapeutic Goods Administration · 2026
- July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee - 07/23/2026, FDA · FDA · 2026
- MHRA Products | Home, MHRA · MHRA · 2026
- TGA warning on the risks of importing unapproved peptide products, Therapeutic Goods Administration · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
- Anaphylaxis: MedlinePlus Medical Encyclopedia, MedlinePlus · MedlinePlus
- Cellulitis: MedlinePlus Medical Encyclopedia, MedlinePlus
- GORALATIDE, NIH NCATS
- GORALATIDE, FDA
- Recognizing medical emergencies: MedlinePlus Medical Encyclopedia, MedlinePlus
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.